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Cathinones, such as mephedrone (Meph), are often co-abused with alcoholic drinks. In 
the present study we investigated the combined effects of Meph plus ethanol (EtOH) 
on neurotransmitter release in the nucleus accumbens (NAc) and the medial prefrontal 
cortex (mPFC).  
A guide canula was stereotaxically implanted into either the NAc or the mPFC of male 
Sprague-Dawley rats. 7 days after surgery a microdialysis probe was inserted and rats 
were administered saline, EtOH (1 g/kg, i.p.), Meph (25 mg/kg, s.c.) or their 
combination and dialysates were collected. Serotonin (5-HT), dopamine (DA) and their 
metabolites (5-HIAA, DOPAC and HVA) were determined through high pressure liquid 
chromatography coupled to mass spectrometry.  
5-HT and DA peaked 40 min after Meph administration (with or without EtOH co-
treatment) in both areas. EtOH combined with Meph increased the 5-HT release 
compared with the rats receiving Meph alone (85% in NAc,  65% in mPFC) although 
the overall change in the area under the curve only reached statistical significance in 
the NAc. In mPFC, the increased release of 5-HT lasted longer in the combination than 
in the Meph group. Moreover, EtOH potentiated the psychostimulant effect of Meph 
measured as locomotor activity. Given that both 5-HT and DA are also related with 
reward and impulsivity, the observed effects point to an increased risk of abuse liability 
when combining Meph with EtOH compared with consuming these drugs alone. 
 
 







































































Mephedrone (4-methylmethcathinone, Meph) is one of the most popular new designer 
drugs of the cathinones’ group. It is a β-keto-amphetamine which has powerful 
psychostimulant and entactogenic effects and has been distributed as bath salts or as 
a component of ecstasy tablets (Brunt et al. 2012).  
Most recreational drug use occurs in leisure environments, where alcoholic drinks are 
omnipresent, so most cathinone consumers combine them with it (O’Neill and McElrath 
2012) and interaction between drugs and alcohol may occur. In fact, the effects of the 
combination of another popular amphetamine derivative, 3,4-
methylenedioxymethamphetamine (MDMA), with alcohol were broadly studied by the 
group of Cassel, Jones and colleagues (see Mohamed et al 2009 for a review), 
showing that alcohol potentiates the hyperlocomotion and conditioning (Cassel et al. 
2004; Jones et al. 2010) effects of MDMA, increases brain MDMA concentrations (Ben 
Hamida et al. 2009) and attenuates its hyperpyretic effects.   
Studies in animals have shown that Meph stimulates the release of serotonin (5-HT), 
dopamine (DA), and norepinephrine and inhibits their re-uptake in the CNS (Baumann 
et al. 2012; Kehr et al. 2011; López-Arnau et al. 2012). Ethyl alcohol (EtOH) also exerts 
complex effects on neurotransmitter release (see Clapp et al. 2008 and Siggins et al. 
2005 for reviews) due to its ability to cross biological membranes and to interact on 
several molecular targets (i.e. ligand-gated ion channels such as glutamate receptors) 
which can lead to uncertain interactions affecting the behavioral and toxic effects when 
combined with Meph, such as increased hyperlocomotion and place conditioning in 
mice (Ciudad-Roberts et al. 2015, 2016). EtOH is capable of increasing 
hyperlocomotion by inhibiting GABAergic interneurons in the substantia nigra reticulata, 
which leads to disinhibition and increased burst firing of dopamine neurons in the 
nucleus accumbens (NAc), but it also increases DA release in other areas of 




































































tegmental area, and more particularly the activation of nicotinic receptors, contribute to 
the increased DA release within the NAc. Also, activation of the opioid reward pathway 
has been reported (Mitchell et al. 2012). On the other hand, systemic and local (Riegert 
et al. 2008) EtOH increases the release of 5-HT in the striatum, suggesting the 
participation of local mechanisms, and an inhibitory effect of EtOH at the serotonin 
transporters has been reported as well (Daws et al. 2006). At the same time, 5-HT was 
found to potentiate the EtOH-induced activation of ventral tegmental area neurons 
(Brodie et al. 1995). 
Other groups have investigated the effects of Meph on neurotransmitter release 
(Baumann et al. 2012; Golembiowska et al. 2016; Kehr et al. 2011; Wright et al. 2012) 
but none has studied such effects in combination with ethanol. The aim of the present 
study is to assess the effects of such drug combination on DA and 5-HT release in the 
nucleus accumbens (NAc) and medial prefrontal cortex (mPFC), two key areas 
involved in drug-induced behavior (Nestler 2001; Hammerslag et al. 2014). Also, the 






Abbreviations: 5-HIAA, 5-Hydroxyindoleacetic acid; 5-HT, serotonin; DA, dopamine; 
DOPAC, 3,4-Dihydroxyphenylacetic acid; EtOH, alcohol/ethanol; LC-MS, liquid 
chromatography-mass spectrometry; MDMA, 3,4-methylenedioxy-methamphetamine; 






































































Animals and drug 
Male Sprague-Dawley rats (Charles River, Spain) weighing 250-300 g were used. They 
were housed two to three per cage at 22 ± 1 oC with an humidity of 50-55%, food and 
water ad libitum and under a normal light/dark cycle (lights on for 12 h starting at 8:00 
AM). After surgery, they were individually housed in order to avoid damaging of the 
cannula guide implant. Pure racemic Meph hydrochloride was synthesized and 
characterized in our laboratory as described previously (López-Arnau et al. 2012).  
Microdialysis experiments 
The microdialysis experiments were carried out on awake rats (n= 3-4/group) 
according to the protocol described by Kehr et al., (2011), with some modifications. An 
intracerebral guide cannula (Agntho’s, Lidingö, Sweden) was surgically implanted in 
rats at the NAc (2.2 mm anterior to bregma (AP), 1.6 mm lateral (L) and 6.0 mm ventral 
to the dura surface (V)) or mPFC (3.2 mm (AP), 0.5 mm (L) and 1.6 mm (V)). Rats 
were allowed at least one week for recovery from surgery. On the evening before an 
experiment, a microdialysis probe (Agntho’s, Lidingö, Sweden; 2 or 3 mm membrane 
length with 15000 Da cut-off) was inserted into the guide cannula and perfused 
overnight with artificial cerebrospinal fluid solution (148 mM NaCl, 2.2 mM CaCl2, 0.8 
mM MgCl2, 1.2 mM Na2HPO4 and 0.3 mM NaH2PO4) at a flow rate of 0.6 µL/min. On 
the next day, after a stabilization period of 2 h, microdialysis samples were collected at 
20 min intervals (flow 1 µL/min). The first three samples were used for estimation of 
basal levels of DA, 5-HT, DOPAC, HVA and 5-HIAA. Thereafter, saline, Meph (25 
mg/kg s.c.), EtOH (1 g/kg i.p.), or both were injected to separate groups of rats and the 
fractions were collected for 180 min and stored at -80oC before analysis. At the end of 
the experiments, the animals were perfused with paraformaldehyde and examined for 




































































placements were included in the study. Of the 32 rats that underwent a successful 
surgical process and were tested in microdialysis experiments, 4 were excluded due to 
missed cannula placement. 
The dose of Meph (25 mg/kg) was chosen according to a previous work showing 
powerful psychostimulant effects of this drug (Martinez-Clemente et al. 2013) and, 
although it may model an acute consumption of Meph in humans (López-Arnau et al. 
2015), previous microdialysis assays only studied the effect of lower doses (Baumann 
et al. 2012; Golembiowska et al. 2016; Kehr et al. 2011; Wright et al. 2012). The dose 
of EtOH (1 g/kg) is a low/moderate dose that does not produce marked behavioral 
effects when administered once for the first time (Imperato and Di Chiara 1986; 
Brabant et al. 2014) and when administered to rats weighing 250-300 g leads to a 
blood ethanol concentration (BEC) of around 0.6 g/L (Bloom et al. 1982). In humans, 
this BEC can easily be reached after a moderate recreational consumption. 
LC-MS/MS determination of DA, 5-HT and metabolites in dialysate samples 
An Agilent 1290 Liquid Chromatography (LC) system equipped with an autosampler 
and coupled to AB Sciex QTRAP 6500 mass spectrometer (MS) was used to quantify 
DA, 5-HT and metabolites. Chromatographic separation was achieved in a Discovery 
HS F5 (150 mm x 4 mm, 3 µm, Sigma-Aldrich, St. Louis, MO, USA) pentafluorophenyl 
column thermostated at 37 oC. The mobile phase was water (A) and methanol (B) with 
0.1% of formic acid in both solvents. An increasing linear gradient (v/v) of B was used 
(t(min), %B), as follows, (0, 0), (0.5, 0), (5.90, 30), (6, 100), (9, 100), (9.10, 0), (10.0, 0) 
at a constant flow rate (500 µl/min). The flow was directed to waste for the first 2 min to 
prevent the inorganic ions of aCSF solution to enter the mass spectrometer. The 
microdialysate samples were refrigerated at 4 ºC and 20 µL was injected, without 
sample pretreatment, into the LC-MS/MS system. Mass spectrometric quantification in 
positive ion mode was carried out using the following transitions: DA (m/z 154 → 137 




































































→ 77, CE of 24 V), 5-HT (m/z 177 → 160, CE of 13 V) and 5-HIAA (m/z 192 → 146, 
CE of 23 V). A negative ion mode was used in the analysis of HVA (m/z 181 → 122, 
CE of -20 V). 
Locomotor activity recording 
The locomotor responses induced by Meph (25 mg/kg, s.c.), EtOH (1 g/kg, i.p.) and 
their combination were assessed in black Plexiglass open field arenas (l x w x h: 45 × 
45 × 40 cm) under low-light conditions. Two days before testing, the animals were 
handled for 10 min, administered saline (1 ml/kg) and placed in the arena for 
habituation. The test day, the rats were administered with the assigned treatment, 
placed in the arenas and their horizontal travelling were video-monitored by a zenithal 
video-camera coupled to a computer running a tracking software (Smart 3.0, Panlab, 
S.L.U., Barcelona, Spain) for 90 min. Both cumulative distances in 10-min blocks and 
total travelled distances were obtained. 
 
Data analysis 
All data are expressed as mean ± standard error of the mean (S.E.M.). All statistical 
calculations were performed using InVivoStat software (http://invivostat.co.uk/). The 
power of the analysis was assessed for all determined monoamines and areas resulted 
higher than 95% for an n value of 3-4 animals per group. The temporal evolution of 
monoamine levels and locomotor activities were analyzed performing a 3-way ANOVA 
for repeated measures with between-subjects variables Meph and  EtOH, and a within-
subjects variable “time”. Differences among AUCs of monoamine levels in dialysates 
and among total distances travelled were assessed through 2-way ANOVA, with Meph 
and EtOH as variables. The α error probability was set at 0.05. Significant differences 
were analyzed using a multiple comparison adjustment of p values (Bonferroni and 




































































calculations of AUCs were performed using GraphPAD Prism 6.00 (GraphPAD 
Software, La Jolla, California. USA, www.graphpad.com).  
 
Results 
Effects on 5-HT and DA release 
Administration of Meph alone (25 mg/kg, s.c.) produced an increase of both 5-HT and 
DA in the NAc (Fig. 1a and 1b) and the mPFC (Fig. 1c and 1d) which peaked 40 min 
after the injections and declined until around 180 min, with the exception of mPFC, 
where dialysate DA levels were still increased at this time point (Fig 1d). In NAc, the 
release of 5-HT was much higher (around 10000-15000%) than that of DA (around 
5000-6000%), whereas in mPFC the increases of both 5-HT and DA where in a similar 
range (3000-4000%).  
As can be seen in Figs. 1a, 1c, 2a and 2c, ethanol combined with Meph provoked an 
increase in released 5-HT compared with the rats receiving Meph alone (85% in NAc,  
65% in mPFC; % of AUC higher than Meph alone), although the overall change in AUC 
only reached statistical significance in the NAc (P<0.01). When analyzing the 5-HT 
values along time, 3-way ANOVA showed significant effect of Meph treatment and 
interaction between Meph and time in both NAc and mPFC. Moreover, the 3-way 
ANOVA revealed a significant interaction between Meph and EtOH in NAc (F1,10 = 9.37, 
P = 0.01, Fig 1a). Post-hoc analyses reported that ethanol potentiated the serotonergic 
increase induced by Meph along the time points between 20 and 120 min in NAc (Fig. 
1a) and at 60 min in the mPFC (Fig 1c). In the latter region, the significantly increased 
release of 5-HT with respect to saline lasted longer in the combination than in the Meph 
group (120 min vs. 60 min). 
Similarly to 5-HT, DA time-course values in NAc showed significant effects of Meph 




































































coadministration of EtOH in NAc. In fact, post-hoc comparisons revealed a significant 
difference between Meph and Meph+EtOH groups at 60 min postadministration (3732 
± 291% release in Meph group ; 5182 ± 532% in Meph+EtOH group). However, when 
considering the total DA released during 180 min, analysis of AUC reported an 
increase of 38%, that did not reach statistical significance (Fig. 2b).  
In mPFC, although 3-way ANOVA revealed effect of time and Meph treatment on DA 
levels in Meph and Meph+EtOH groups, no differences were observed between them 
(Figs 1d and 2c).  
EtOH alone, at the dose we used, had no significant effect in both DA and 5-HT basal 
levels in the studied brain areas.  
Effects on 5-HT and DA metabolites 
The levels of 5-HIAA showed a slight and non-significant increase (by 10%) in the 
EtOH-treated rats (Fig. 2b and 2d). Conversely, 5-HIAA values were significantly 
decreased by 25% in the rats receiving Meph alone. The 2-way ANOVA analysis 
revealed a significant interaction between Meph and EtOH in both NAc and mPFC, 
suggesting that EtOH potentiates the decrease in 5-HIAA induced by Meph (NAc: F1,10 
= 5.57, P<0.05; mPFC: F1,10 = 3.29, P<0.05).   
Effects on locomotor activity 
Meph administration significantly increased locomotor activity with respect to saline and 
EtOH (Fig 3). Moreover, when Meph was combined with EtOH the increase in 
locomotion was significantly potentiated with respect to Meph alone and 3-way ANOVA 
revealed a significant interaction between EtOH and Meph (F1,20 = 7.78; P = 0.01). The 







































































Alcoholic drinks are frequently combined with the new psychostimulant substances 
such as Meph (Elliott and Evans, 2014). Alcohol enhances the subjective effects of 
other drugs of abuse such as MDMA, and studies have shown that it increases its 
rewarding and psychostimulant effects (Ben Hamida et al. 2009). Similarly, our group 
reported that alcohol increases Meph-induced conditioned place preference and 
psychostimulant properties in mice (Ciudad-Roberts et al. 2015). 
These previous results led us to perform microdialysis studies to assess the effects of 
such combination on the release of DA and 5-HT in two key areas involved in drug-
induced behavior, namely the NAc and mPFC. Release of DA in the NAc is a key 
process related with the reinforcing and rewarding properties of a drug (Nestler 2001) 
and this area projects to other regions which are directly related with drug-induced 
behavior such as the mPFC. For instance, the mPFC is involved in the establishment 
of motor (Dalley et al. 2004) and amphetamine-induced (Hammerslag et al. 2014) 
impulsivity.  
We found an increased release of neurotransmitters after administration of Meph in 
both studied brain areas, being the increases of 5-HT much higher than those of DA, 
which is in agreement with previous reports (Golembiowska et al. 2016; Kehr et al. 
2011; Wright et al. 2012). Nevertheless the increase in DA (peaking around 4000%) 
was more than sufficient to account for the rewarding effects of the drug. The 
percentages of increase in neurotransmitters release are over the double than those 
reported by Wright et al. (2012) in rats administered with 10 mg/kg of Meph (peaks of 
around 1000% for DA and 2200% for 5-HT in the NAc) which indicates a clear dose-
response relationship.  
The overall 3-way ANOVA of DA levels along time did not reveal a significant 




































































NAc, a tendence to potentiation of DA release was observed in the Meph + EtOH 
group with respect to Meph alone between 20 and 100 min post-administration. In fact, 
the post-hoc test showed a significant difference at 60 min. This slight increase might 
account for increased rewarding effects. Previous experiments in mice point in this 
direction (Ciudad-Roberts et al. 2015). By contrast, we found a significant potentiation 
of Meph-induced 5-HT release by EtOH in NAc. The increase in 5-HT was much higher 
than that of DA and the addition of EtOH did not change this proportionality, which 
contrasts with the work by Riegert et al. (2008) using superfused striatal slices and 
reporting that addition of EtOH shifted the MDMA-induced monoamine overflow 
towards higher DA release. This difference could be mainly explained by the different 
inhibition profile of Meph and MDMA at DA and 5-HT transporters: Meph shows IC50 for 
DA and 5-HT uptake inhibition of the same order of magnitude, whereas MDMA shows 
a much higher potency inhibiting 5-HT than DA uptake (Hadlock et al. 2011). Also the 
examined areas (striatum vs. NAc), doses and the different techniques may partially 
contribute to such difference. In mPFC, the overall interaction between Meph and EtOH 
did not reach statistical significance, although the post-hoc analysis revealed a 
significant potentiation of 5-HT release by combination with EtOH at the 60 min time 
point. 
The effects of EtOH are multiple and complex (reviewed by Clapp et al. 2008 and 
Siggins et al. 2005), including increased release of DA in the NAc. However, at the 
dose we used, EtOH alone had few or no significant effect on neurotransmitter levels, 
suggesting that the effect in animals receiving the drug combination are due to a 
synergistic pharmacodynamic or pharmacokinetic interaction rather than to a simple 
addition. A number of interactions of EtOH with other drugs have been reported. For 
example, Ben Hamida et al. (2009) demonstrated that ethanol is capable of increasing 
the concentration of MDMA in areas with high DA transmission (striatum and frontal 




































































description was found for this effect, we cannot rule out a similar pharmacokinetic 
interaction between ethanol and Meph in the brain areas we studied.  
The increase in DA and 5-HT in the rats receiving Meph was accompanied by a 
decrease in the levels of their metabolites. This can be attributed to monoamine uptake 
inhibition by Meph (Baumann et al., 2012, López-Arnau et al., 2012) because the key 
enzyme in the metabolism of DA and 5-HT, namely monoaminoxidase (MAO), is 
localized inside the nerve terminal, so that monoamines have to be taken up to be 
metabolized. As Meph blocks reuptake, a decrease in metabolites is detected despite 
the increase in monoamine release. A similar effect was described by Kehr et al. 
(2011). This mechanism is backed by the fact that EtOH alone, which induces DA 
release but does not inhibit uptake, does not produce a decrease, but rather tends to 
increase the metabolites. Statistical analysis revealed a significant interaction between 
Meph and EtOH treatment with respect to 5-HIAA levels, suggesting that Meph exerts 
a higher blockade of the transporter in presence of EtOH. A direct effect of EtOH on 
serotonin transporter can be ruled out because a decrease in 5-HIAA levels should 
have been shown in the EtOH group (Daws et al. 2006). Therefore, this is in agreement 
with the possibility of a pharmacokinetic interaction beforehand mentioned, leading to 
increased interstitial levels of Meph that would further prevent 5-HT reuptake and 
metabolism. Additional studies need to be performed to corroborate this hypothesis. 
Similar results were described by Cassel et al. (2005) when studying the effects of 
MDMA combined with EtOH on monoamine levels and their metabolites. 
To assess whether the observed potentiation of neurotransmitter release in the 
Meph+EtOH group had a measurable effect on the psychostimulant properties of 
Meph, we performed locomotor activity experiments in rats using the same doses and 
combinations that we did in the microdialysis assays. The results demonstrated that the 
combination of EtOH with Meph potentiates the psychostimulant effects of the 




































































neurotransmitters. The observed increases in 5-HT-release could be responsible of 
such potentiation of locomotor activity. In fact, previous works demonstrate a role of 5-
HT receptors on Meph-induced hyperlocomotion as it was reduced by administration of 
ketanserin (López-Arnau et al. 2012; Ciudad-Roberts et al. 2015). Moreover, elevated 
5-HT release in the mPFC positively relates with motor impulsivity, which is related with 
drug relapse (Dalley et al., 2002; Hammerslag et al., 2014). 
To sum up, in this work we demonstrate a potentiation of the increase in monoamines 
release and in psychostimulant effects when combining Meph plus EtOH which might 
involve increased psychostimulant subjective effects and therefore increased abuse 
liability. Therefore an experimental-based warning concerning the risks regarding the 
combined consumption of these drugs could be conveyed to the population at large. 
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Fig. 1 Effects of saline, ethanol (EtOH, 1 g/kg, i.p.), mephedrone (Meph, 25 mg/kg, 
s.c.) and their combination on NAc (a, b) and mPFC (c, d) 5-HT and DA levels, 
expressed as a percentage of baseline neurotransmitter levels. All points show mean ± 
S.E.M. from 3-4 rats. Dialysate samples were collected every 20 min. The arrows show 
when drugs were injected. The relevant results of 3-way ANOVA are included in the 
table below each panel. Post-hoc test results are indicated on the graphs.  ***P<0.001, 
**P<0.01, *P<0.05 Meph vs. saline group; ###P<0.001, ##P<0.01, #P<0.05 Meph+EtOH 
vs. saline group; $$$P<0.001, $$P<0.01, $P<0.05 Meph+EtOH vs. Meph group. The 
tracings from saline and EtOH groups practically overlap 
Fig. 2 Effects of saline, ethanol (EtOH, 1 g/kg, i.p.), mephedrone (Meph, 25 mg/kg, 
s.c.) and their combination on the levels of 5-HT, DA and their metabolites (5-HIAA and 
DOPAC, respectively) in NAc (a, b) and mPFC (c, d). Levels are expressed as the area 
under the curve comprised between the time points 0 and 180 min. All the bars show 
mean ± S.E.M. from 3-4 rats. The relevant results of 2-way ANOVA are included in the 
table below each panel. Post-hoc test results are indicated on the graphs. ***P<0.001, 
**P<0.01, *P<0.05 vs. saline group; @@@P<0.001, @@P<0.01, @P<0.05 vs. EtOH group; 
##P<0.01 between the indicated groups 
Fig. 3 Effects of saline, ethanol (EtOH, 1 g/kg, i.p.), mephedrone (Meph, 25 mg/kg, 
s.c.) and their combination on horizontal locomotor activity in rats. Travelled distances 
were recorded in 10 min blocks and depicted in panel a, whereas total distances are 
depicted in panel b. All points show mean ± S.E.M. from 6 rats per group. The relevant 
results of ANOVAs are included in the table below each panel. Post-hoc test results are 
indicated on the graphs. **P<0.01, *P<0.05 Meph vs. saline group; ###P<0.001, 
##P<0.01, #P<0.05 Meph+EtOH vs. saline group; $$$P<0.001, $$P<0.01, $P<0.05 
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